Drug
Kpt 330
Kpt 330: highest development phase Phase 1, developed by Karyopharm Therapeutics, United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Karyopharm Therapeutics, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| KPT-330 NCT02091245 | Phase 1 | Relapsed Acute Lymphoblastic Leukemia (ALL) |
| KPT-330 NCT02471911 | Phase 1 | Diffuse Large B-Cell Lymphoma |
Latest
No recent events.
Follow Kpt 330 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.